Cargando…
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15 mg demonstrate...
Autores principales: | Lingvay, Ildiko, Mosenzon, Ofri, Brown, Katelyn, Cui, Xuewei, O’Neill, Ciara, Fernández Landó, Laura, Patel, Hiren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039543/ https://www.ncbi.nlm.nih.gov/pubmed/36964557 http://dx.doi.org/10.1186/s12933-023-01797-5 |
Ejemplares similares
-
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023) -
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023) -
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023) -
Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
por: Lee, Clare J, et al.
Publicado: (2023) -
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)